Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma

Inclusion Criteria

• •1. Previously untreated, histologically confirmed mantle cell lymphoma,
• •2. Measurable or evaluable disease (at least one site with \>1.5 cm in diameter
• •3. All stages are eligible
• •4. Age \> 18 years
• •5. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2
• •6. Adequate hepatic function:
• •* Bilirubin \< 3 mg/dL
• •* Transaminases (serum glutamic oxaloacetic transaminase (SGOT) and/or serum glutamate-pyruvate transaminase (SGPT)) \< than 2.5 times the upper limit of normal for the institution, unless due to lymphomatous involvement
• •7. Serum creatinine\< 1.5 mg/dl
• •8. Ability to give informed consent
• •9. Women of childbearing potential must have a negative pregnancy test within 72 hours of entering into the study. Males and females must agree to use adequate birth control if conception is possible during the study. Women must avoid pregnancy and men avoid fathering children while in the study.
• •10. Life expectancy greater than 6 months.